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Purpose: We reviewed the literature on chronic inﬂammatory demyelinating polyneuropathy (CIDP) in
diabetes mellitus (DM) and explored real-world data on the prevalence and treatment of CIDP within DM.
Methods: A literature search of Scopus was performed for the terms chronic inﬂammatory demyelinating
polyradiculoneuropathy, chronic inﬂammatory demyelinating polyneuropathy, CIDP, and prevalence, incidence,
epidemiology, or diabetes; peripheral neuropathy and prevalence or diabetes. We also searched through the
reference lists of the resulting publications for additional ﬁndings that may have been missed. Additional
publications on guidelines for the diagnosis of CIDP and diabetic neuropathy were also included. A descriptive
analysis of the 2009–2013 PharMetrics Plus™ Database was performed to estimate the prevalence and
treatment of CIDP within the DM population.
Results: There is an increasing body of literature suggesting that the prevalence of CIDP tends to be higher in
diabetic patients, especially in those of older age. Our real-world data seem to support published ﬁndings
from the literature. For the total cohort (N = 101,321,694), the percent prevalence of CIDP (n = 8,173) was
0.008%; DM (n = 4,026,740) was 4%. The percent prevalence of CIDP without DM (n = 5,986) was 0.006%;
CIDP with DM (n = 2,187) was 9-fold higher at 0.054%. For patients N50 years old, there was a signiﬁcantly
higher percentage of CIDP with DM than CIDP without DM. Approximately 50% of CIDP patients were treated
with IVIg, 23%–24% with steroids, 1%–2% with PE, and 20%–23% received no treatment.
Conclusions: In addition to the growing evidence of higher prevalence of CIDP in DM, our ﬁndings reinforce the
need for heightened awareness of the association of CIDP and DM.ant fun
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heterogeneous, progressive or relapsing–remitting, immune-
mediated disorder of the peripheral nervous system that has an
estimated prevalence of 1–8.9 per 100,000 (Chio, Cocito, Bottacchi,
et al., 2007; Hafsteinsdottir, Olafsson, & Stefansson, 2012; Laughlin,
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Rajabally, Simpson, Beri, et al., 2009). The epidemiology of CIDP varies
depending on the diagnostic criteria used (Rajabally, Simpson, et al.,
2009). CIDP has typical and atypical phenotypic variants (Mathey,
Park, Hughes, et al., 2015). Only half of CIDP patients have typical
CIDP, which exhibits symmetrical sensory and motor symptoms. The
remainder has atypical disease, which presents with predominantly
focal, sensory, motor, distal or asymmetrical symptoms. Despite
increased efforts to identify a biomarker, there is no deﬁnitive
diagnostic marker for CIDP, and recognition of CIDP is not straight-
forward in some cases due to its heterogeneous nature (Jann,
Bramerio, Beretta, et al., 2003; Latov, 2011; Sommer & Toyka, 2011).
A thorough literature search of Scopus—an abstract and citation
database of peer-reviewed literature—was performed for all publica-
tions, including but not limited to case reports, reviews, clinical
studies, meeting abstracts, book chapters, for the terms chronic
inﬂammatory demyelinating polyradiculoneuropathy, chronicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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incidence, epidemiology, or diabetes; peripheral neuropathy and
prevalence or diabetes. We also searched through the reference lists
of the resulting publications for additional ﬁndings that may have
been missed. All publications included were in the English language,
and there was no limit on year of publication. Additional publications
on guidelines for the diagnosis of CIDP and diabetic neuropathy were
also included.1. Diagnosis of CIDP
The diagnosis of CIDP is based on the recognition of clinical
features, neurological examination, and electrodiagnostic criteria.
Electrodiagnostic studies include electromyograms and nerve con-
duction studies (NCSs). Nerve conduction studies and electrophysi-
ological evidence of demyelination are required to conﬁrm the
diagnosis (AAN, 1991; EFNS/PNS, 2010; Krarup, 2003; Latov, 2014;
Tesfaye, Boulton, Dyck, et al., 2010), while laboratory testing, elevated
protein levels in cerebrospinal ﬂuid (CSF), and nerve biopsy can help
rule out other causes for neuropathy and support the diagnosis (EFNS/
PNS, 2010; Koller, Kieseier, Jander, et al., 2005). As the disease
progresses, electrophysiological evidence of axonal damage may
become superimposed on the demyelinating CIDP features (Hughes,
Allen, Makowska, et al., 2006). Patients with CIDP typically present
with progressive weakness in both proximal and distal muscles,
areﬂexia, sensory symptoms with proximal weakness, and preferen-
tial loss of sensation for vibration or joint position (EFNS/PNS, 2010).
Clinical observations of muscle weakness and loss of sensation are
manifestations of nerve demyelination that result in conduction
blocks and delays in conduction speed.
The 2010 European Federation of Neurological Societies/Periph-
eral Nerve Society (EFNS/PNS) guidelines are globally accepted for
both clinical and research purposes (EFNS/PNS, 2010; French & Vallat,
2008; Koski, Baumgarten, Magder, et al., 2009; Rajabally, Fowle, & Van
den Bergh, 2015; Rajabally, Nicolas, Pieret, et al., 2009) due to their
balance between high sensitivity (73.2%) and speciﬁcity (90.8%) for
CIDP (Breiner & Brannagan, 2014; Rajabally, Simpson, et al., 2009;
Rajabally et al., 2015). In contrast, the American Academy of
Neurology (AAN) criteria (AAN, 1991) can have a sensitivity as low
as 3.6% and a speciﬁcity of 100% for CIDP. The EFNS/PNS guidelines
deﬁne CIDP as “deﬁnite,” “probable,” or “possible” based on speciﬁcs
surrounding motor distal latency prolongation, reduction of motor
conduction velocity, prolongation or absence of F-waves, motor
conduction block, and distal compound muscle action potential
(CMAP) duration (EFNS/PNS, 2010). Testing of multiple limbs is
more sensitive than testing of unilateral or lower limbs in optimizing
electrodiagnostic testing for CIDP, particularly in atypical CIDP (Chin,
Deng, Bril, et al., 2015; Rajabally, Jacob, & Hbahbih, 2005; Vo,
Hanineva, Chin, et al., 2015). Additional tests that may be needed to
support a diagnosis of CIDP are elevated CSF protein with a leukocyte
count less than 10/mm3, magnetic resonance imaging (MRI) of the
lumbosacral or cervical nerve roots or the brachial or lumbosacral
plexuses, nerve biopsy, and clinical improvement after immunomod-
ulatory treatment (Abe, Terashima, Hoshino, et al., 2015; EFNS/PNS,
2010; Midroni, de Tilly, Gray, et al., 1999). Newer techniques for
detecting proximal demyelination as well as treatment response
include ultrasonography (Di Pasquale, Morino, Loreti, et al., 2015;
Guidon, 2015; Jang, Cho, Yang, et al., 2014; Kerasnoudis, Pitarokoili,
Behrendt, et al., 2014; Kerasnoudis, Pitarokoili, Behrendt, et al., 2015;
Kerasnoudis, Pitarokoili, Gold, et al., 2015), magnetic stimulation of
the cauda equine (Maccabee, Eberle, Stein, et al., 2011), somatosen-
sory evoked potentials (Devic, Petiot, & Mauguiere, 2015), MRI
gadolinium enhancement of the spinal nerve roots (Midroni et al.,
1999), and magnetic resonance neurography with 3-dimensional
reconstruction to determine patterns of nerve hypertrophy and todifferentiate the pathophysiology of CIDP subtypes (Shibuya, Sugiyama,
Ito, et al., 2015).
2. Diabetes mellitus and diabetic neuropathies
According to the Centers for Disease Control and Prevention, DM
affects about 9.3% of the general population in the United States in
contrast to 25.9% in persons 65 years or older (CDC, 2014). Type 2 DM
(T2DM) results in insulin resistance and accounts for N90% of cases
(Handelsman, Mechanick, Blonde, et al., 2011; Russell & Zilliox, 2014).
The prevalence of T2DM increases with age, elevated body mass
index, and family history (Handelsman et al., 2011). Due to the
gradual onset of T2DM, early symptoms often go unrecognized
(Russell & Zilliox, 2014). Some investigators report CIDP to be more
frequent in patients with T2DM (Dunnigan, Ebadi, Breiner, et al.,
2013), while others report equal occurrence of CIDP in type 1 DM and
T2DM (Sharma, Cross, Ayyar, et al., 2002). While it is estimated that
50% of patients with DM have some form of neuropathy, more than
80% of these cases are diabetic peripheral neuropathy (DPN)—a
length-dependent, sensory more than motor, axonal neuropathy
(Chin & Rubin, 2010). Early signs of DPN manifest through distal loss
of sensation in the feet and/or loss of deep tendon reﬂexes at the
ankles. The risk of developing DPN increases with the duration of DM
and glycemic control, and DPN may precede the formal diagnosis of
DM by years (Chin & Rubin, 2010; Handelsman et al., 2011; Russell &
Zilliox, 2014).
3. Controversy: the association of CIDP and DM
In the 1975 seminal paper on CIDP (Dyck, Lais, Ohta, et al., 1975),
Dr Peter J. Dyck stated, “Patients with diabetes mellitus […] who had a
neuropathy whose clinical, neurophysiologic, and pathologic features
were indistinguishable from the neuropathy studied here, have not
been included under this designation [of CIDP] even though it may
be shown eventually that pathogenetic mechanisms may be similar
or alike.”
Forty years later, the association between CIDP and DM is still
being debated. Diagnosing CIDP in a patient with DM is more
challenging, as superimposed axonal damage can obscure electro-
physiology ﬁndings of CIDP, and DPN can cause elevated CSF protein
(Gorson, Ropper, Adelman, et al., 2000). One study has reported that
the occurrence of CIDP is 11-fold higher in diabetic than nondiabetic
patients; however, this was a smaller nonpopulation based study
(Sharma, Cross, Farronay, et al., 2002). Another study estimated that
CIDP occurs in 9% of patients with DM (Lozeron, Nahum, Lacroix, et al.,
2002), while others have reported that there is no association
between CIDP and DM (Dyck, Engelstad, Norell, et al., 2010; Laughlin
et al., 2009). One publication stated that an overemphasis on
electrophysiological criteria may cause confusion in the perceived
association between CIDP and DM (Laughlin et al., 2009). However,
that study was retrospective, had a small CIDP population (only 19
patients met the Mayo Clinic clinical and electrophysiological criteria
for CIDP), was from a relatively limited patient demographic, and had
only 1 patient with both CIDP and DM. Moreover, full electrophys-
iological characteristics of subjects were not reported. A subsequent
report by the same authors investigated whether painless diabetic
motor neuropathy might represent CIDP (Garces-Sanchez, Laughlin,
Dyck, et al., 2011). Based on clinical presentation, electrophysiology,
and a strong emphasis on sural nerve biopsy, the authors concluded
that painless diabetic motor neuropathy was a painless form of
diabetic lumbosacral radiculoplexus neuropathy, not CIDP.
Patients with both CIDP and DM tend to have extensive axonal loss
with more severe neuropathy yet may respond to treatment
(Dunnigan, Ebadi, Breiner, et al., 2014; Gorson et al., 2000). A small
study comparing 14 patients with CIDP and DM to 60 patients with
CIDP alone, found that CIDP patients with DMwere older (67 years vs.
Table 2
Treatment details of CIDP patients without and with DM.
CIDP without DM and CIDP with DM
patients (N = 134)
P value
CIDP without DM
(n = 67)
CIDP with DM
(n = 67)
Response to treatment (n = 100) 0.71
Non-responders, n (%) 29 (45) 17 (49)
Responders, n (%) 36 (55) 18 (51)
Treatment provided, n (%) 62 (93) 36 (57) b0.0001⁎
IVIg, n (%) 58 (87) 33 (52) b0.0001⁎
Prednisone, n (%) 44 (67) 12 (19) b0.0001⁎
PE, n (%) 10 (15) 3 (5) 0.040
Azathioprine, n (%) 36 (55) 7 (11) b0.0001⁎
Mycophenolate mofetil, n (%) 9 (14) 6 (10) 0.460
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roids, intravenous immunoglobulin (IVIg), plasma exchange (PE), and
cyclophosphamide (Gorson et al., 2000). Patients with CIDP and DM
exhibited more severe axonal loss, likely the result of underlying
diabetic axonal polyneuropathy (Dunnigan et al., 2013). In contrast to
patients with DPN (n = 56), diabetic patients with CIDP (n = 67)
had more extensive slowing of motor nerve conduction velocity
(32.4 ± 6.4 m/s vs. 35.2 ± 3.4 m/s, P = 0.006). Diabetic patients
with CIDP also tended to be older (65.1 ± 13.7 years vs. 55 ±
16 years, P = 0.0003), have shorter duration of diabetes (16.5 ±
13.5 years vs. 24.0 ± 15.6 years, P = 0.005), have more severe
neuropathy (ie, higher Toronto Clinical Neuropathy Score, higher
vibration perception threshold, and more weakness), and have better
glycemic control compared with diabetic patients who did not have
CIDP but had slowed conduction velocities (HbA1c 7.7 ± 2.0% vs.
9.6 ± 2.4%, P = 0.003).
EFNS criteria are less predictive of treatment response in CIDP
patients with DM (Abraham, Breiner, Katzberg, et al., 2015). CIDP
patients with DM were more likely to respond to treatment if they
fulﬁlled 2 EFNS/PNS electrophysiological criteria whereas CIDP
patients without diabetes were likely to respond with only 1 criterion
met (Table 1). In diabetics, fulﬁlling more diagnostic criteria for CIDP
(more evidence of demyelinating neuropathy on NCSs) was associ-
ated with higher response rates to treatment (Cocito, Chio, Tavella,
et al., 2006). The recent retrospective study (Dunnigan et al., 2014)
also demonstrated that patients with CIDP and DM were less likely to
be treated even though they had similar response rates to treatment
as CIDP patients without DM and higher rates of proximal weakness
and ataxia (Table 2).
4. Real-world data analysis of health insurance administrative
claims
4.1. Methods
4.1.1. Database description
Controversies on the overlap of CIDP within DM led us to
investigate the prevalence of CIDP and DM in a “real-world” health
insurance administrative claims database—the 2009–2013 Phar-
Metrics Plus™ Database (Watertown, MA, USA). Secondary objectives
were to determine any impact of age on the diagnosis of CIDP patients
both without and with DM and to highlight any differences in
treatment patterns. This database represents a pooling of adjudicated
medical and pharmacy claims for over 100 million patient lives
from more than 90 different health plans across the United States.
The database includes inpatient and outpatient diagnoses in Interna-
tional Classiﬁcation of Diseases-9th Revision-Clinical ModiﬁcationTable 1
Response-to-therapy rates based on number of EFNS/PNS criteria met.
Treatment responders % (n)
EFNS/PNS criteria Whole cohort CIDP without DM CIDP with DM
0 30 (8/27) 31 (5/16) 27 (3/11)
1 53 (20/38) 58 (14/24) 43 (6/14)
2 72 (13/18) 67 (8/12) 83 (5/6)
3 78 (7/9) 67 (4/6) 100 (3/3)
4 71 (5/7) 71 (5/7) –
OR⁎ (CI) 1.83 (1.22, 2.74) 1.53 (0.99, 2.36) 3.73 (1.32, 10.60)
P 0.003 0.05 0.01
Table adapted from Abraham A et al. Expert Rev Clin Immunol 2015;11(4):537-546 with
permission.
⁎* Odds ratio calculated by logistic regression with treatment responder (yes or no) as
thedependent variable. CI, conﬁdence interval; CIDP, chronic inﬂammatorydemyelinating
polyneuropathy; DM, diabetes mellitus; EFNS/PNS, European Federation of Neurological
Societies/Peripheral Nerve Society; OR, odds ratio.(ICD-9-CM) format; procedures in Current Procedural Terminology-
4th Edition and the Healthcare Common Procedure Coding System;
and prescription records (Blanchette, Roberts, Petersen, et al., 2011).
It also includes demographic variables, product and insurance type,
provider specialty, and dates inclusive of plan enrollment. This private
database includes a limited number of patients enrolled in Medicaid
or Medicare and, therefore, underrepresents the patient population
older than 65 years. A typical limitation of any claims database
analysis is that clinical data are unavailable for the diagnostic
criteria by which the diagnoses of CIDP and DM were made. To
ensure the robustness of this dataset, we applied stringent inclusion
criteria. Patients were conﬁrmed with DM if there were ≥2 claims
based on ICD-9-CM code 250. For a CIDP conﬁrmation, patients
were required to have ≥2 CIDP claims (ICD-9-CM code 357.81)
reported at least 90 days apart. Incident cases were deﬁned as being
free of a CIDP diagnosis during the 12-month baseline period before
their index date.
4.1.2. Statistical analysis
Descriptive statistics were used to assess differences in the
population. Chi-square tests were used to assess differences in age
distributions between CIDP patients without and with DM. Statistical
signiﬁcance was set at an alpha level of 0.05. This study was exempt
from any institutional review board review because the patient
information within the database was de-identiﬁed.
4.2. Results of database analysis
In this retrospective database study (N = 101,321,694), the
prevalence of patients with CIDP (n = 8,173) was 8 per 100,000
persons (0.008%), which was similar to a previously reportedLoading dose IVIg (2 g/kg) 1.86 ± 0.4 1.97 ± 0.4 0.230
IVIg treatments, n (range) 22.4 ± 39.6 (1–200) 7.02 ± 12.2 (0–60) 0.020
Response to IVIg treatment, n (%) 46 (84) 18 (56) 0.006
PE treatments, n (range) 1.4 ± 0.9 (1–3) 4.7 ± 0.6 (4–5) 0.0002⁎
Response to PE treatment, n (%) 9 (82) 2 (67) 0.590
Clinical status (n = 100) 0.130
Worse, n (%) 16 (25) 4 (11)
No change, n (%) 13 (20) 13 (37)
Stabilized, n (%) 21 (32) 8 (23)
Improved, n (%) 15 (23) 10 (29)
NCS after treatment (n = 93) 0.850
Worse, n (%) 8 (14) 6 (18)
Stable, n (%) 48 (81) 26 (76)
Improved, n (%) 3 (5) 2 (6)
Table adapted from Dunnigan SK et al. PLoS One. 2014;9(2):e89344 with permission.
Data are mean ± SD unless otherwise indicated. Differences in categorical variables
were assessed in three-group comparisons using the χ2-test, while differences in
continuous variables were assessed using the analysis of variance.
⁎* Bonferroni corrected P value for signiﬁcance = 0.003. CIDP, chronic immune
demyelinating polyneuropathy; DM, diabetes mellitus; IVIg, intravenous
immunoglobulin; PE, plasma exchange; NCS, nerve conduction study; SD, standard
deviation.
1404 V. Bril et al. / Journal of Diabetes and Its Complications 30 (2016) 1401–1407prevalence value of 8.9 per 100,000 persons (Laughlin et al., 2009).
Reﬂective of the generally younger patient population in the database,
the overall prevalence of patients with DM (n = 4,026,740) was
3,974 per 100,000 persons (4.0%), which was lower than the 9.3%
reported in the general United States population (CDC, 2014).
However, in the population older than 55 years (n = 2,461,140),
the percent prevalence of patients with DM was 11,567 per 100,000
persons (11.6%). The prevalence of CIDP among nondiabetic patients
(n = 5,986) was 6 per 100,000 persons (0.006%). In contrast, the
prevalence of CIDP in the diabetic population (n = 2,187) was 9-fold
higher at 54 per 100,000 persons (0.054%). In this claims database
study, clinical data are not available, and the accuracy of the diagnoses
for DM and CIDP cannot be conﬁrmed; yet the relative risk of having
both CIDP and DM at 9-fold higher than having CIDP alone is
approaching the 11-fold increase previously reported by Sharma et al.,
using the highly speciﬁc AAN criteria (Sharma, Cross, et al., 2002).
To improve the stringency around the CIDP diagnosis in this
epidemiological cohort, we mandated that conﬁrmed CIDP cases have
distinct ICD-9-CM codes reported at least 90 days apart. A total of
2,048 patients had conﬁrmed CIDP with ≥12 months pre- and
post-index periods and ICD-9-CM codes of at least 90 days apart.
Within this conﬁrmed CIDP group, 1,411 (69%) patients had CIDP
without DM, and 637 (31%) patients had CIDP with DM. These data
were similar to the 25.7% of patients who had clinically conﬁrmed
CIDP with DM in another database study (Kalita, Misra, & Yadav,
2007). In our current study, the median ± standard deviation (SD)
age was 56.4 ± 14.5 years for CIDP without DM and 61.6 ±
11.8 years for CIDP with DM. In patients aged 50 years or younger,
CIDP without DM was more common than CIDP with DM (P b 0.01)
(Fig. 1), suggesting that misdiagnosis of CIDP was not likely in this
dataset. No difference in prevalence rates was found in patients aged
51 to 60 years in both groups (29.98% CIDP without DM vs. 31.08%
CIDP with DM, P = 0.61). In those aged 61 to 70 years, there was a
trend for CIDP with DM to be more common than CIDP without DM,
but statistical signiﬁcance was not reached (33.28% CIDP without DM
vs. 29.34% CIDP with DM, P = 0.07). Despite the relatively smallerFig. 1. Percent patient distribution by age. Patients (n = 2,048) had conﬁrmed CIDP with ≥12
apart. CIDP, chronic inﬂammatory demyelinating polyneuropathy; DM, diabetes mellitus.number of patients in the 2 highest age groups, the percentage of
patients aged ≥71 years with CIDP and DM was statistically
signiﬁcantly higher than those without DM (P b 0.01). In addition,
the treatment of CIDP patients without or with a concomitant
diagnosis of DM was found to be similar. Approximately 50% of
patients were treated with IVIg (57% CIDP without DM and 52%
CIDP with DM), 23%–24% with steroids, 1%–2% with PE; and
approximately 20%–23% received no treatment in both groups
(Fig. 2). Although clinical data are not available, one might
hypothesize that these untreated patients had only mild disability
and therefore, according to EFNS/PNS guidelines, would be managed
with monitoring for disease worsening (EFNS/PNS, 2010). Notably,
steroid and IVIg use was similar between both groups. As only claim
data were available, we cannot comment on the responsiveness of
these patients to various treatments.
In an alternative analysis evaluating this database with less
stringent inclusion criteria (ie, ≥2 CIDP claims reported at no
particular time interval), the reliability of this dataset became more
evident. Without requiring the CIDP claims to be reported at least
90 days apart, we found similar results to those derived from the
more stringent analysis previously described. A total of 3,399 patients
had conﬁrmed CIDP; 2,380 (70%) patients had CIDP without DM; and
1,019 (30%) patients had CIDP with DM. Comparable to the data
described in Fig. 1, the age distribution derived from this less stringent
analysis demonstrated: (A) CIDPwithout DMwasmore common than
CIDP with DM (P = 0.01) in patients aged b50 years; (B) there was
no difference in patients aged 51 to 60 years for both groups (29%
CIDP without DM and 30% CIDP with DM, P = 0.36); however, (C)
CIDP with DM was statistically signiﬁcantly higher than CIDP without
DM in patients aged N61 years (P = 0.01). Treatment of CIDP patients
without or with a concomitant diagnosis of DM also appeared
consistent with data described in Fig. 2 (approximately 40% of
patients were treated with IVIg, 27%with steroids, 1%–2%with PE, and
roughly 30% received no treatment).
Interestingly, the CIDP patient age distribution in this large United
States database was similar to the age distribution observed in anmonths pre- and post-index period based on ICD-9-CM codes reported at least 90 days
Fig. 2. Treatment by percentage for CIDP patients with and without DM. Patients (n = 2,048) had conﬁrmed CIDP with ≥12 months pre- and post-index period based on ICD-9-CM
codes reported at least 90 days apart. CIDP, chronic inﬂammatory demyelinating polyneuropathy; DM, diabetes mellitus; IVIg, intravenous immunoglobulin; PE, plasma exchange.
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patients had a higher prevalence of CIDP than younger patients
(Chio et al., 2007).We, thus, conclude that diabetes may be a common
comorbidity along with CIDP in patients older than 50 years. Despite
the potential selection bias for fewer patients older than 65 years (due
to a limited number of patients ≥65 years old enrolled in Medicare),
we expect that such bias would not only underestimate the
prevalence of DM observed, but also underestimate the associated
prevalence of patients with CIDP and DM.
5. Treatment of CIDP with DM
At present, the decision on how to treat CIDP with DM is guided by
treatment for CIDP without DM. CIDP is the most common treatable
autoimmune neuropathy (Mathey et al., 2015); up to 80% of patients
with CIDP respond to treatment. Clinical studies have shown that
corticosteroids, PE, and IVIg all have efﬁcacy in CIDP (Dyck, Daube,
O'Brien, et al., 1986; Dyck, O'Brien, Oviatt, et al., 1982; Hahn, Bolton,
Pillay, et al., 1996a; Hughes, Donofrio, Bril, et al., 2008; Mehndiratta &
Hughes, 2002; Rajabally, 2015). The EFNS/PNS guidelines (EFNS/PNS,
2010) recommend IVIg or corticosteroids for sensory andmotor CIDP;
IVIg for pure motor CIDP; and if IVIg and corticosteroids are both
ineffective, PE should be considered. Combination treatment or the
addition of an immunosuppressant or immunomodulatory drug may
be considered if the response to IVIg, corticosteroids, or PE is
inadequate. Several clinical studies have shown that patients with
CIDP and DM are also responsive to immunological treatment (Cocito,
Ciaramitaro, Isoardo, et al., 2002; Dunnigan et al., 2014; Gorson et al.,
2000; Jann, Bramerio, Facchetti, et al., 2009; Krendel, Costigan, &
Hopkins, 1995; Sharma, Cross, et al., 2002a; Stewart, McKelvey,
Durcan, et al., 1996). Treatment decisions depend on factors such as
concomitant diseases, cost, therapeutic responsiveness, adverse
effects particularly with long-term treatment, and a risk of relapse
upon treatment withdrawal (Jann et al., 2009; Rajabally, 2015).
Regardless of a DM diagnosis, our data demonstrated that steroid
treatment in both groups occurred at similar rates (27%).
While IVIg may be preferred in severe disease states due to its
rapid therapeutic onset, overtreatment should be avoided (Rajabally,
2015). Once maximal beneﬁt from treatment has been achieved, it is
recommended to gradually wean or even withdraw treatment
(Eftimov, Vermeulen, van Doorn, et al., 2012; Hahn, Bolton,
Zochodne, et al., 1996; Lünemann et al., 2015; RMC Trial Group,
2009). Improvements in the monitoring of CIDP response totreatment with consistent, standardized, and serial functional scores
are needed to help physicians determine the effectiveness of a chosen
therapy and avoid overtreatment. These objective measures are now
required by a number of health insurance providers to continue
therapy.6. Distinguishing CIDP with concomitant diabetes from DPN
Although population-based studies have less controlled inclusion
and exclusion criteria than traditional randomized, controlled trials
(RCTs), this work provides meaningful real-world data that could not
otherwise be described by clinical data from RCTs. As described by
Booth and Tannock (Booth & Tannock, 2014), population-based
studies include all patients within a given jurisdiction, including the
underrepresented, the elderly, and those with comorbidity; thus, they
are less prone to selection and referral biases that affect more
traditional forms of observational research. The magnitude of the
number of patients in this CIDP databasewith a concomitant diagnosis
of DM indicates a need for heightened awareness of the association of
CIDP and DM. This large data analysis, albeit retrospective, does
highlight the need to differentiate CIDP in patients with concomitant
DM, as this distinction is important to provide appropriate treatment.
While this database demonstrates that CIDP is diagnosed in DM, it
remains unclear whether it is accurately diagnosed and whether
adequate tools exist to aid in diagnosis. A recent publication suggested
that misdiagnosis of CIDP is common (Allen & Lewis, 2015). We
recognize that the number of patients in our database with a diagnosis
of CIDP may be an overestimation, and if such overestimation
occurred, we would expect the same level of impact on both the
general CIDP population and the DM population. In the past, nerve
biopsy was used to diagnose atypical CIDP. Today, nerve biopsy is
seldom performed, as it is felt to be less sensitive than electro-
diagnosis, and furthermore, speciﬁc abnormalities may be more
difﬁcult to detect because “inﬂammatory lesions in CIDP occur
predominantly in the spinal roots, proximal nerve trunks, and major
plexuses” (Mathey et al., 2015). Histological ﬁndings from sural nerve
biopsy in CIDP are variable and nonspeciﬁc (Barohn, Kissel, Warmolts,
et al., 1989; Dyck et al., 1975; Matsumuro, Izumo, Umehara, et al.,
1994; Stewart et al., 1996), making it difﬁcult “to distinguish between
CIDP and DPN on histological grounds alone”(Stewart et al., 1996).
There are “no distinctive pathological ﬁndings among these [CIDP
with DM vs. DPN] patients” (Uncini, De Angelis, Di Muzio, et al., 1999).
1406 V. Bril et al. / Journal of Diabetes and Its Complications 30 (2016) 1401–1407Although not yet validated in large populations, a screening tool
has been proposed wherein clinicians could use a combination of
clinical, electrophysiological, and laboratory parameters to more
accurately identify CIDP versus DPN in patients with DM (Lotan,
Hellman, & Steiner, 2015). Certain parameters supportive of CIDP and
not seen in DPN were given a positive (+) value (eg, progressive/
relapsing motor weakness of 2–6 months and distal CMAP duration of
≥9 ms in ≥1 nerve and ≥1 other demyelinating parameter in ≥1 other
nerve). Other parameters seen in DPN but not in CIDP were given a
negative (−) value (eg, slowly progressive course and reduced CMAP
amplitude disproportionate tomotor conduction velocities). Although
validated in a small number of patients (N = 57), this tool correlates
well with both AAN and EFNS criteria for CIDP (AAN, 1991; Van den
Bergh & Pieret, 2004). Further studies with larger populations
correlating with EFNS/PNS diagnostic criteria and, importantly,
response to therapy, are needed (Lotan et al., 2015).
7. Conclusion
There is an increasing body of literature suggesting that the
prevalence of CIDP tends to be higher in diabetic patients, especially in
those of older age. Our real-world data seem to support published
ﬁndings from the literature. This retrospective health insurance
administrative claims database study suggests that the prevalence
of CIDP in a nondiabetic population is 6 per 100,000 persons, while the
prevalence of CIDP in a patient population with DM is 9-fold higher at
54 per 100,000 persons. The association of CIDP with DM remains
controversial, as both diseases have increased prevalence in patients
over age 50 years. It is a challenge to identify CIDP in a diabetic
population due to concomitant axonal damage. Although some
patients with CIDP and DM respond to treatment, it is difﬁcult to
predict response. Because of the rising prevalence of DM throughout
the world, there is a need to differentiate CIDP from DPN accurately.
The overarching goal is to determine which patients with DM have a
treatable neuropathy. New biomarkers for CIDP, such as corneal
confocal microscopy (Stettner, Hinrichs, Guthoff, et al., 2016), are
being evaluated in DPN as well as CIDP and may help differentiate
these entities in the future.
Acknowledgments
This study was funded by Grifols, manufacturer of IVIg. We, the
authors, thank Latoya M. Mitchell, PhD, CMPP, for medical writing
assistance. We also thank Tam Nguyen-Cao, PhD, and June Davis, PhD,
both of Grifols for editorial assistance. Data contained within this
manuscriptwerepresentedat theAmericanDiabetesAssociationMeeting
in Boston, MA, on June 8, 2015, the Peripheral Nerve Society Biennial
Meeting inQuebec City, Canada on June 29, 2015, and theNeurodiab 25th
Annual Meeting in Elsinore, Denmark on September 13, 2015.
References
AAN (1991). Research criteria for diagnosis of chronic inﬂammatory demyelinating
polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American
Academy of Neurology AIDS Task Force. Neurology, 41(5), 617–618.
Abe, Y, Terashima, H, Hoshino, H, Sassa, K, Sakai, T, Ohtake, A, ... Yamanouchi, H (2015).
Characteristic MRI Features of Chronic Inﬂammatory Demyelinating Polyradiculo-
neuropathy. Brain and Development, 37(9), 894–896. http://dx.doi.org/10.1016/j.
braindev.2015.01.006.
Abraham, A, Breiner, A, Katzberg, HD, Lovblom, LE, Perkins, BA, & Bril, V (2015).
Treatment responsiveness in CIDP patients with diabetes is associated with unique
electrophysiological characteristics, and not with common criteria for CIDP. Expert
Review of Clinical Immunology, 11(4), 537–546. http://dx.doi.org/10.1586/
1744666X.2015.1018891.
Allen, JA, & Lewis, RA (2015). CIDP diagnostic pitfalls and perception of treatment
beneﬁt . Neurology , 8(6), 498–504. http://dx.doi .org/10.1212/WNL.
0000000000001833.
Barohn, RJ, Kissel, JT, Warmolts, JR, & Mendell, JR (1989). Chronic inﬂammatory
demyelinating polyradiculoneuropathy. Clinical Characteristics, course, and rec-
ommendations for diagnostic criteria. Archives of Neurology, 46(8), 878–884.Blanchette, CM, Roberts, MH, Petersen, H, Dalal, AA, & Mapel, DW (2011). Economic
burden of chronic bronchitis in the United States: A retrospective case-control
study. International Journal of Chronic Obstructive Pulmonary Disease, 6, 73–81.
http://dx.doi.org/10.2147/COPD.S15882.
Booth, CM, & Tannock, IF (2014). Randomised controlled trials and population-based
observational research: Partners in the evolution of medical evidence. British
Journal of Cancer, 110(3), 551–555. http://dx.doi.org/10.1038/bjc.2013.725.
Breiner, A, & Brannagan, TH, III (2014). Comparison of sensitivity and speciﬁcity among
15 criteria for chronic inﬂammatory demyelinating polyneuropathy. Muscle &
Nerve, 50(1), 40–46. http://dx.doi.org/10.1002/mus.24088.
CDC (2014).National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the
United States (trans: Services U.S.D.o.H.a.H.). Atlanta, GA: Centers for Disease Control
and Prevention.
Chin, RL, Deng, C, Bril, V, Hartung, HP, Merkies, IS, Donofrio, PD, ... Latov, N (2015).
Follow-up nerve conduction studies in CIDP after treatment with IVIG-C:
Comparison of patients with and without subsequent relapse. Muscle & Nerve,
52(4), 498–502. http://dx.doi.org/10.1002/mus.24624.
Chin, RL, & Rubin, M (2010). Diabetic Neuropathy. In L. Poretsky (Ed.), Principles of
Diabetes Mellitus (pp. 357–370) (2nd ed.). New York: Springer.
Chio, A, Cocito, D, Bottacchi, E, Buffa, C, Leone, M, Plano, F, ... The PARCIDP (2007).
Idiopathic chronic inﬂammatory demyelinating polyneuropathy: An epidemiolog-
ical study in Italy. Journal of Neurology, Neurosurgery, and Psychiatry, 78(12),
1349–1353. http://dx.doi.org/10.1136/jnnp.2007.114868.
Cocito, D, Chio, A, Tavella, A, Poglio, F, Paolasso, I, Ciaramitaro, P, ... Isoardo, G (2006).
Treatment response and electrophysiological criteria in chronic inﬂammatory
demyelinating polyneuropathy. European Journal of Neurology : the ofﬁcial journal of
the European Federation of Neurological Societies, 13, 669–670.
Cocito, D, Ciaramitaro, P, Isoardo, G, Barbero, P, Migliaretti, G, Pipieri, A, ... Durelli, L
(2002). Intravenous immunoglobulin as ﬁrst treatment in diabetics with
concomitant distal symmetric axonal polyneuropathy and CIDP. Journal of
Neurology, 249(6), 719–722. http://dx.doi.org/10.1007/s00415-002-0698-0.
Devic, P, Petiot, P, & Mauguiere, F (2015). Diagnostic utility of somatosensory evoked
potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral
demyelination. Muscle & Nerve, 53(1), 78–83. http://dx.doi.org/10.1002/mus.24693.
Di Pasquale, A, Morino, S, Loreti, S, Bucci, E, Vanacore, N, & Antonini, G (2015).
Peripheral nerve ultrasound changes in CIDP and correlations with nerve
conduction velocity. Neurology, 84(8), 803–809. http://dx.doi.org/10.1212/WNL.
0000000000001291.
Dunnigan, SK, Ebadi, H, Breiner, A, Katzberg, HD, Lovblom, LE, Perkins, BA, & Bril, V
(2013). Comparison of diabetes patients with "demyelinating" diabetic sensori-
motor polyneuropathy to those diagnosed with CIDP. Brain and Nehavior, 3(6),
656–663. http://dx.doi.org/10.1002/brb3.177.
Dunnigan, SK, Ebadi, H, Breiner, A, Katzberg, HD, Barnett, C, Perkins, BA, & Bril, V (2014).
The characteristics of chronic inﬂammatory demyelinating polyneuropathy in
patients with and without diabetes–an observational study. PloS One, 9(2), e89344.
http://dx.doi.org/10.1371/journal.pone.0089344.
Dyck, PJ, Daube, J, O'Brien, P, Pineda, A, Low, PA, Windebank, AJ, & Swanson, C (1986).
Plasma exchange in chronic inﬂammatory demyelinating polyradiculoneuropathy.
The New England Journal of Medicine, 314(8), 461–465. http://dx.doi.org/10.1056/
NEJM198602203140801.
Dyck, PJB, Engelstad, JK, Norell, JE, Laughlin, RS, Garces-Sanchez, M,Massie, R, & Dyck, PJ
(2010). inﬂammatory neuropathies in diabetes mellitus: The radiculoplexus
neuropathies and diabetic CIDP. Journal of the Peripheral Nervous System: The
Ofﬁcial Journaal of The Peripheral Nerve Society, 15, 241–293.
Dyck, PJ, Lais, AC, Ohta, M, Bastron, JA, Okazaki, H, & Groover, RV (1975). Chronic
Inﬂammatory Polyradiculoneuropathy. Mayo Clinic Proceedings, 50(11), 621–637.
Dyck, PJ, O'Brien, PC, Oviatt, KF, Dinapoli, RP, Daube, JR, Bartleson, JD, ... Windebank, AJ
(1982). prednisone improves chronic inﬂammatory demyelinating polyradiculo-
neuropathy more than no treatment. Annals of Neurology, 11(2), 136–141. http://
dx.doi.org/10.1002/ana.410110205.
EFNS/PNS (2010). European Federation of Neurological Societies/Peripheral Nerve
Society Guideline on management of chronic inﬂammatory demyelinating
polyradiculoneuropathy: Report of a joint task force of the European Federation
of Neurological Societies and the Peripheral Nerve Society—First Revision. Journal of
the Peripheral Nervous System: The Ofﬁcial Journaal of The Peripheral Nerve Society,
15(1), 1–9. http://dx.doi.org/10.1111/j.1529-8027.2010.00245.x.
Eftimov, F, Vermeulen, M, van Doorn, PA, Brusse, E, van Schaik, IN, & PREDICT Study
Group (2012). Long-Term Remission of CIDP after Pulsed Dexamethasone or Short-
Term Prednisolone Treatment. Neurology, 78(14), 1079–1084. http://dx.doi.org/10.
1212/WNL.0b013e31824e8f84.
French CIDP Study Group, & Vallat, JM (2008). Recommendations on diagnostic
strategies for chronic inﬂammatory demyelinating polyradiculoneuropathy.
Postgraduate Medical Journal, 84(993), 378–381. http://dx.doi.org/10.1136/jnnp.
2006.109785.
Garces-Sanchez, M, Laughlin, RS, Dyck, PJ, Engelstad, JK, Norell, JE, & Dyck, PJ (2011).
Painless diabetic motor neuropathy: A variant of diabetic lumbosacral radiculo-
plexus neuropathy? Annals of Neurology, 69(6), 1043–1054. http://dx.doi.org/10.
1002/ana.22334.
Gorson, KC, Ropper, AH, Adelman, LS, & Weinberg, DH (2000). Inﬂuence of diabetes
mellitus on chronic inﬂammatory demyelinating polyneuropathy. Muscle & Nerve,
23(1), 37–43.
Guidon, AC (2015). Comment: A growing role for nerve ultrasound in diagnosis and
management of CIDP? Neurology, 84(8), 808. http://dx.doi.org/10.1212/WNL.
0000000000001295.
Hafsteinsdottir, B, Olafsson, E, & Stefansson, S (2012). The incidence and prevalence of
CIDP in Iceland. American Neurological Association, M1448, S75.
1407V. Bril et al. / Journal of Diabetes and Its Complications 30 (2016) 1401–1407Hahn, AF, Bolton, CF, Pillay, N, Chalk, C, Benstead, T, Bril, V, ... Feasby, TE (1996). Plasma-
Exchange Therapy in Chronic Inﬂammatory Demyelinating Polyneuropathy. A
Double-Blind, Sham-Controlled, Cross-over Study. Brain: a Journal of Neurology,
119(Pt 4), 1055–1066.
Hahn, AF, Bolton, CF, Zochodne, D, & Feasby, TE (1996). Intravenous immunoglobulin
treatment in chronic inﬂammatory demyelinating polyneuropathy. A double-blind,
placebo-controlled, cross-over study. Brain: a Journal of Neurology, 119(Pt 4), 1067–1077.
Handelsman, Y, Mechanick, JI, Blonde, L, Grunberger, G, Bloomgarden, ZT, Bray, GA, ...
AACE Task Force for Developing a Diabetes Comprehensive Care Plan (2011).
American Association of Clinical Endocrinologists Medical Guidelines for Clinical
Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine
Practice : Ofﬁcial Journal of the American College of Endocrinology and the American
Association of Clinical Endocrinologists, 17(Suppl. 2), 1–53.
Hughes, RA, Allen, D, Makowska, A, & Gregson, NA (2006). Pathogenesis of chronic
inﬂammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral
Nervous System: The Ofﬁcial Journaal of The Peripheral Nerve Society, 11(1), 30–46.
http://dx.doi.org/10.1111/j.1085-9489.2006.00061.x.
Hughes, RA, Donofrio, P, Bril, V, Dalakas, MC, Deng, C, Hanna, K, ... ICE Study Group
(2008). Intravenous immune globulin (10% caprylate-chromatography puriﬁed)
for the treatment of chronic inﬂammatory demyelinating polyradiculoneuropathy
(ICE study): a randomised placebo-controlled trial. The Lancet Neurology, 7(2),
136–144. http://dx.doi.org/10.1016/S1474-4422(07)70329-0.
Jang, JH, Cho, CS, Yang, KS, Seok, HY, & Kim, BJ (2014). Pattern analysis of nerve
enlargement using ultrasonography in chronic inﬂammatory demyelinating
polyneuropathy. Clinical Neurophysiology : Ofﬁcial Journal of the International
Federation of Clinical Neurophysiology, 125(9), 1893–1899. http://dx.doi.org/10.
1016/j.clinph.2013.12.115.
Jann, S, Bramerio, MA, Beretta, S, Koch, S, Defanti, CA, Toyka, KV, & Sommer, C (2003).
Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients
with CIDP. Neurology, 61(11), 1607–1610.
Jann, S, Bramerio, MA, Facchetti, D, & Sterzi, R (2009). Intravenous immunoglobulin is
effective in patients with diabetes and with chronic inﬂammatory demyelinating
polyneuropathy: Long term follow-up. Journal of Neurology, Neurosurgery, and
Psychiatry, 80(1), 70–73. http://dx.doi.org/10.1136/jnnp.2008.149013.
Kalita, J, Misra, UK, & Yadav, RK (2007). A comparative study of chronic inﬂammatory
demyelinating polyradiculoneuropathy with and without diabetes mellitus.
European Journal of Neurology: The Ofﬁcial Journal of the European Federation of
Neurological Societies, 14(6), 638–643. http://dx.doi.org/10.1111/j.1468-1331.
2007.01798.x.
Kerasnoudis, A, Pitarokoili, K, Behrendt, V, Gold, R, & Yoon, MS (2014). Nerve
ultrasound score in distinguishing chronic from acute inﬂammatory demyelinating
polyneuropathy. Clinical Neurophysiology : Ofﬁcial Journal of the International
Federation of Clinical Neurophysiology, 125(3), 635–641. http://dx.doi.org/10.1016/
j.clinph.2013.08.014.
Kerasnoudis, A, Pitarokoili, K, Behrendt, V, Gold, R, & Yoon, MS (2015). Bochum
Ultrasound Score Versus Clinical and Electrophysiological Parameters in Distin-
guishing Acute-Onset Chronic from Acute Inﬂammatory Demyelinating Polyneuro-
pathy. Muscle & Nerve, 51(6), 846–852. http://dx.doi.org/10.1002/mus.24484.
Kerasnoudis, A, Pitarokoili, K, Gold, R, & Yoon, MS (2015). Bochum ultrasound score
allows distinction of chronic inﬂammatory frommultifocal acquired demyelinating
polyneuropathies. Journal of the Neurological Sciences, 348(1–2), 211–215. http://
dx.doi.org/10.1016/j.jns.2014.12.010.
Koller, H, Kieseier, BC, Jander, S, & Hartung, HP (2005). Chronic inﬂammatory
demyelinating polyneuropathy. The New England Journal of Medicine, 352(13),
1343–1356. http://dx.doi.org/10.1056/NEJMra041347.
Koski, CL, Baumgarten, M, Magder, LS, Barohn, RJ, Goldstein, J, Graves, M, ... Cornblath,
DR (2009). Derivation and validation of diagnostic criteria for chronic inﬂamma-
tory demyelinating polyneuropathy. Journal of the Neurological Sciences, 277(1–2),
1–8. http://dx.doi.org/10.1016/j.jns.2008.11.015.
Krarup, C (2003). An update on electrophysiological studies in neuropathy. Current
Opinion in Neurology, 16(5), 603–612. http://dx.doi.org/10.1097/01.wco.
0000093104.34793.94.
Krendel, DA, Costigan, DA, & Hopkins, LC (1995). Successful treatment of neuropathies
in patients with diabetes mellitus. Archives of Neurology, 52(11), 1053–1061.
Latov, N (2011). Biomarkers of CIDP in Patients with Diabetes or CMT1. Journal of the
Peripheral Nervous System: The Ofﬁcial Journaal of The Peripheral Nerve Society,
16(Suppl. 1), 14–17. http://dx.doi.org/10.1111/j.1529-8027.2011.00299.x.
Latov, N (2014). Diagnosis and treatment of chronic acquired demyelinating
polyneuropathies. Nature Reviews Neurology, 10(8), 435–446. http://dx.doi.org/
10.1038/nrneurol.2014.117.
Laughlin, RS, Dyck, PJ, Melton, LJ, 3rd, Leibson, C, Ransom, J, & Dyck, PJ (2009). Incidence
and prevalence of CIDP and the association of diabetes mellitus. Neurology, 73(1),
39–45. http://dx.doi.org/10.1212/WNL.0b013e3181aaea47.
Lotan, I, Hellman, MA, & Steiner, I (2015). Diagnostic criteria of chronic inﬂammatory
demyelinating polyneuropathy in diabetes mellitus. Acta Neurologica Scandinavica,
132(4), 278–283. http://dx.doi.org/10.1111/ane.12394.
Lozeron, P, Nahum, L, Lacroix, C, Ropert, A, Guglielmi, JM, & Said, G (2002).
Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic
patients. Journal of Neurology, 249(5), 569–575. http://dx.doi.org/10.1007/
s004150200066.
Lünemann, JD, Nimmerjahn, F, & Dalakas, MC (2015). Intravenous immunoglobulin in
neurology- mode of action and clinical efﬁcacy. Nature Reviews Neurology, 11(2),
80–89. http://dx.doi.org/10.1038/nrneurol.2014.253.
Lunn, MP, Manji, H, Choudhary, PP, Hughes, RA, & Thomas, PK (1999). Chronic
inﬂammatory demyelinating polyradiculoneuropathy: A prevalence study in south
east England. Journal of Neurology, Neurosurgery, and Psychiatry, 66(5), 677–680.Maccabee, PJ, Eberle, LP, Stein, IA, Willer, JA, Lipitz, ME, Kula, RW, ... Amassian, VE
(2011). Upper leg conduction time distinguishes demyelinating neuropathies.
Muscle & Nerve, 43(4), 518–530. http://dx.doi.org/10.1002/mus.21909.
Mathey, EK, Park, SB, Hughes, RA, Pollard, JD, Armati, PJ, Barnett, MH, ... Lin, CS (2015).
Chronic inﬂammatory demyelinating polyradiculoneuropathy: From pathology to
phenotype. Journal of Neurology, Neurosurgery, and Psychiatry, 86(9), 973–985.
http://dx.doi.org/10.1136/jnnp-2014-309697.
Matsumuro, K, Izumo, S, Umehara, F, & Osame, M (1994). Chronic inﬂammatory
demyelinating polyneuropathy: Histological and immunopathological studies on
biopsied sural nerves. Journal of the Neurological Sciences, 127(2), 170–178.
McLeod, JG, Pollard, JD, Macaskill, P, Mohamed, A, Spring, P, & Khurana, V (1999).
Prevalence of chronic inﬂammatory demyelinating polyneuropathy in New South
Wales, Australia. Annals of Neurology, 46(6), 910–913.
Mehndiratta, MM, & Hughes, RA (2002). Corticosteroids for Chronic Inﬂammatory
Demyelinating Polyradiculoneuropathy. The Cochrane Database of Systematic
Reviews, 1, CD002062. http://dx.doi.org/10.1002/14651858.CD002062.
Midroni, G, de Tilly, LN, Gray, B, & Vajsar, J (1999). MRI of the cauda equina in CIDP:
Clinical correlations. Journal of the Neurological Sciences, 170(1), 36–44.
Mygland, Å, & Monstad, P (2001). Chronic polyneuropathies in Vest-Agder, Norway.
European Journal of Neurology : The Ofﬁcial Journal of the European Federation of
Neurological Societies, 8(2), 157–165. http://dx.doi.org/10.1046/j.1468-1331.2001.
00187.x.
Rajabally, YA (2015). Long-term immunoglobulin therapy for chronic inﬂammatory
demyelinating polyradiculoneuropathy.Muscle & Nerve, 51(5), 657–661. http://dx.
doi.org/10.1002/mus.24554.
Rajabally, YA, Fowle, AJ, & Van den Bergh, PY (2015). Which criteria for research in
chronic inﬂammatory demyelinating polyradiculoneuropathy? An analysis of
current practice. Muscle & Nerve, 51(6), 932–933. http://dx.doi.org/10.1002/mus.
24496.
Rajabally, YA, Jacob, S, & Hbahbih, M (2005). Optimizing the use of electrophysiology in
the diagnosis of chronic inﬂammatory demyelinating polyneuropathy: A study of
20 cases. Journal of the Peripheral Nervous System: The Ofﬁcial Journaal of The
Peripheral Nerve Society, 10(3), 282–292. http://dx.doi.org/10.1111/j.1085-9489.
2005.10306.x.
Rajabally, YA, Nicolas, G, Pieret, F, Bouche, P, & Van den Bergh, PY (2009). Validity of
diagnostic criteria for chronic inﬂammatory demyelinating polyneuropathy: A
multicentre European study. Journal of Neurology, Neurosurgery, and Psychiatry,
80(12), 1364–1368. http://dx.doi.org/10.1136/jnnp.2009.179358.
Rajabally, YA, Simpson, BS, Beri, S, Bankart, J, & Gosalakkal, JA (2009). Epidemiologic
variability of chronic inﬂammatory demyelinating polyneuropathy with different
diagnostic criteria: Study of a UK population. Muscle & Nerve, 39(4), 432–438.
http://dx.doi.org/10.1002/mus.21206.
RMC Trial Group (2009). Randomised controlled trial of methotrexate for chronic
inﬂammatory demyelinating polyradiculoneuropathy (RMC Trial): A pilot, multi-
centre study. The Lancet Neurology, 8(2), 158–164. http://dx.doi.org/10.1016/
s1474-4422(08)70299-0.
Russell, JW, & Zilliox, LA (2014). Diabetic neuropathies. Continuum: Lifelong Learning in
Neurology, 20, 1226–1240. http://dx.doi.org/10.1212/01.CON.0000455884.29545.
d2 (5 Peripheral Nervous System Disorders).
Sharma, KR, Cross, J, Ayyar, DR, Martinez-Arizala, A, & Bradley, WG (2002). diabetic
demyelinating polyneuropathy responsive to intravenous immunoglobulin ther-
apy. Archives of Neurology, 59(5), 751–757.
Sharma, KR, Cross, J, Farronay, O, Ayyar, DR, Shebert, RT, & Bradley, WG (2002).
Demyelinating neuropathy in diabetes mellitus. Archives of Neurology, 59(5),
758–765.
Shibuya, K, Sugiyama, A, Ito, SI, Misawa, S, Sekiguchi, Y, Mitsuma, S, ... Kuwabara, S
(2015). Reconstruction magnetic resonance neurography in chronic inﬂammatory
demyelinating polyneuropathy. Annals of Neurology, 77(2), 333–337. http://dx.doi.
org/10.1002/ana.24314.
Sommer, C, & Toyka, K (2011). Nerve biopsy in chronic inﬂammatory neuropathies: In
situ biomarkers. Journal of the Peripheral Nervous System: The Ofﬁcial Journaal of The
Peripheral Nerve Society, 16(Suppl. 1), 24–29. http://dx.doi.org/10.1111/j.1529-
8027.2011.00301.x.
Stettner, M, Hinrichs, L, Guthoff, R, Bairov, S, Petropoulos, IN, Warnke, C, ... Kieseier, BC
(2016). Corneal confocal microscopy in chronic inﬂammatory demyelinating
polyneuropathy. Annals of Clinical and Translational Neurology, 3(2), 88–100. http://
dx.doi.org/10.1002/acn3.275.
Stewart, JD, McKelvey, R, Durcan, L, Carpenter, S, & Karpati, G (1996). Chronic
inﬂammatory demyelinating polyneuropathy (CIDP) in diabetics. Journal of the
Neurological Sciences, 142(1–2), 59–64.
Tesfaye, S, Boulton, AJ, Dyck, PJ, Freeman, R, Horowitz, M, Kempler, P, ... The Toronto
Diabetic Neuropathy Expert Group (2010). Diabetic neuropathies: Update on
deﬁnitions, diagnostic criteria, estimation of severity, and treatments. Diabetes
Care, 33(10), 2285–2293. http://dx.doi.org/10.2337/dc10-1303.
Uncini, A, De Angelis, MV, Di Muzio, A, Callegarini, C, Ciucci, G, Antonini, G, ... Gambi, D
(1999). Chronic inﬂammatory demyelinating polyneuropathy in diabetics: Motor
conductions are important in the differential diagnosis with diabetic polyneuro-
pathy. Clinical Neurophysiology : Ofﬁcial Journal of the International Federation of
Clinical Neurophysiology, 110(4), 705–711.
Van den Bergh, PY, & Pieret, F (2004). Electrodiagnostic criteria for acute and chronic
inﬂammatory demyelinating polyradiculoneuropathy. Muscle & Nerve, 29(4),
565–574. http://dx.doi.org/10.1002/mus.20022.
Vo, ML, Hanineva, A, Chin, RL, Carey, BT, Latov, N, & Langsdorf, JA (2015). Comparison of
2-limb versus 3-limb electrodiagnostic studies in the evaluation of chronic
inﬂammatory demyelinating polyneuropathy. Muscle & Nerve, 51(4), 549–553.
http://dx.doi.org/10.1002/mus.24424.
